Format

Send to

Choose Destination
Diabetes Care. 2017 Jan;40(1):63-68. doi: 10.2337/dc16-1525. Epub 2016 Nov 4.

Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial.

Author information

1
Department of Endocrinology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands j.kropff@amc.nl.
2
King's College London, London, U.K.
3
Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
4
Bournemouth University, Bournemouth, U.K.
5
Joint Clinical Research Facility, Swansea University, Swansea, U.K.
6
Profil, Neuss, Germany.
7
Profil, Mainz, Germany.
8
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
9
Research, Senseonics Inc., Germantown, MD.
10
Department of Endocrinology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

Abstract

OBJECTIVE:

It is known that continuous glucose monitoring (CGM) systems can lower mean glucose compared with episodic self-monitoring of blood glucose. Implantable CGM systems may provide additional benefits.

RESEARCH DESIGN AND METHODS:

We studied the Eversense (Senseonics Inc.) implantable CGM sensor in 71 participants aged 18 years and older with type 1 and type 2 diabetes in a 180-day multinational, multicenter pivotal trial. Participants used the CGM system at home and in the clinic. CGM accuracy was assessed during eight in-clinic visits with the mean absolute relative difference (MARD) for venous reference glucose values >4.2 mmol/L as the primary end point. Secondary end points included Clarke Error Grid Analysis and alarm performance. The primary safety outcome was device-related serious adverse events. This trial is registered with ClinicalTrials.gov, number NCT02154126.

RESULTS:

The MARD value against reference glucose values >4.2 mmol/L was 11.1% (95% CI 10.5, 11.7). Clarke Error Grid Analysis showed 99.2% of samples in the clinically acceptable error zones A and B. Eighty-one percent of hypoglycemic events were detected by the CGM system within 30 min. No device-related serious adverse events occurred during the study.

CONCLUSIONS:

Our results indicate the safety and accuracy of this new type of implantable CGM system and support it as an alternative for transcutaneous CGM.

PMID:
27815290
DOI:
10.2337/dc16-1525
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center